Arrowhead Research ARWR EBITDA

EBITDA at other companies

Ionis PharmaceuticalsIONS

-$98.16M-169%

ALN

Alnylam PharmaceuticalsALNY

$245.34M+10,980%

Assembly BiosciencesASMB

-$11.34M-14.5%

Arbutus Biopharma CorporationABUS

$168.92M+766%

Ultragenyx PharmaceuticalRARE

-$67M+32.3%

Beam TherapeuticsBEAM

-$101.61M+10.7%

FAQ

What is Arrowhead Research's EBITDA?

Arrowhead Research (ARWR) reported EBITDA of -$134.89M in Q1 2026.

How has Arrowhead Research's EBITDA changed year-over-year?

Arrowhead Research's EBITDA decreased by 134.8% year-over-year, from $387.29M to -$134.89M.

What is the long-term trend for Arrowhead Research's EBITDA?

Over 4 years (2021 to 2025), Arrowhead Research's EBITDA has grown at a -3.5% compound annual growth rate (CAGR), from -$140.77M to $122.27M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.